Novavax COVID-19 vaccine as a second dose generates high immune response in young people, finds study

Reactions were mostly mild-to-moderate, with fewest reactions in the fractional Pfizer-BioNTech group
Participants in the fractional Pfizer-BioNTech group were more likely to have a breakthrough infection than the standard Pfizer-BioNTech and Novavax groups Antibody responses were similar for all three groups at 236 days after second doses were administered